Cargando…
Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China
The aim of this study was to evaluate the safety of an antiviral regimen of protease inhibitors combined with Arbidol (umifenovir) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients. The genomic sequence of SARS-CoV-2 is highly homologous to that of SARS-CoV (Zhou et...
Autores principales: | Guo, Yong-zheng, Xu, Kai-jin, Li, Yong-tao, Fu, Jia-dan, Xu, Min, Yu, Ling, Sheng, Ji-fang, Zhu, Biao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Zhejiang University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759455/ https://www.ncbi.nlm.nih.gov/pubmed/33843160 http://dx.doi.org/10.1631/jzus.B2000204 |
Ejemplares similares
-
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
por: Wang, Xi, et al.
Publicado: (2020) -
Tobacco Knowledge among Adults in Zhejiang Province, China
por: Xu, Yue, et al.
Publicado: (2013) -
Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats
por: HU, Yunzhen, et al.
Publicado: (2021) -
Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020
por: Tong, Zhen-Dong, et al.
Publicado: (2020) -
Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China
por: Xiang, Wei-ling, et al.
Publicado: (2020)